RFG Advisory Group LLC lifted its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 125.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,961 shares of the biopharmaceutical company’s stock after buying an additional 5,539 shares during the quarter. RFG Advisory Group LLC’s holdings in Bristol-Myers Squibb were worth $557,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. First Trust Advisors LP boosted its position in Bristol-Myers Squibb by 10.7% during the 2nd quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock valued at $24,130,000 after acquiring an additional 41,892 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Bristol-Myers Squibb by 54.0% in the 1st quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after purchasing an additional 162,884 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Bristol-Myers Squibb by 1.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after purchasing an additional 3,833 shares in the last quarter. Dividend Assets Capital LLC acquired a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth $737,000. Finally, Quantitative Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth $6,150,000. Hedge funds and other institutional investors own 69.14% of the company’s stock.

A number of equities analysts recently issued reports on BMY shares. UBS AG restated a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a research note on Monday, October 9th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets reiterated a “sell” rating and set a $49.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Finally, Citigroup Inc. lifted their price objective on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $64.93.

Shares of Bristol-Myers Squibb Company (BMY) opened at $61.68 on Tuesday. The company has a market cap of $101,835.48, a P/E ratio of 21.02, a PEG ratio of 2.45 and a beta of 1.18. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 EPS. analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.23% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-stake-raised-by-rfg-advisory-group-llc/1684411.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.